Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

12.23 +0.42 (+3.60%)
Streaming Delayed Price Updated: 11:07 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
32 33 Next >
News headline image
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
News headline image
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances. 
Via Talk Markets
News headline image
Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript ↗
CMPS earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program ↗
COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing:  
Via Benzinga
News headline image
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
News headline image
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
News headline image
COMPASS Pathways announces CFO transition
From COMPASS Pathways
Via GlobeNewswire
News headline image
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
News headline image
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
News headline image
Psychedelic-Compound-Based Drug Stocks Continue To Fall ↗
The 5 constituents in our Psychedelic Drug Stocks Index were down 10.1% this week (-6.3% last week) and are now down 39.2% since the end of July. 
Via Talk Markets
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
--News Direct-- 
Via News Direct
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
By Faith Ashmore, Benzinga 
Via TheNewswire.com
News headline image
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It ↗
Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among... 
Via Benzinga
News headline image
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares 
Via Benzinga
News headline image
Major Psychedelic Drug Stocks Continued To Decline This Week ↗
A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news. 
Via Talk Markets
News headline image
COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care ↗
The Current Landscape Of Mental Health Is Failing Patients 
Via Benzinga
News headline image
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
News headline image
September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗
Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining... 
Via Talk Markets
News headline image
Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher ↗
Psychedelic stocks should be part of a growth investor's portfolio due to the industry's ability to deliver strong return. 
Via InvestorPlace
News headline image
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
News headline image
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Artificial Intelligence
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
--News Direct-- 
Via News Direct
Topics Artificial Intelligence
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
By Faith Ashmore, Benzinga 
Via TheNewswire.com
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
--News Direct-- 
Via News Direct
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing ↗
Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by... 
Via Benzinga
News headline image
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
News headline image
Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative ↗
The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (&e 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.